Use of erythropoietin for the preventive or curative treatment of cardiac failure
CA 2476538 C · Owner: Van Gilst, Wiekert Hendrikus · Inventors: Brus, Ronald Hendrik Peter; Van Gilst, Wiekert Hendrikus; De Boer, Rudolf Allert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides for the use of erythropoietin or a derivative or , functional analogue thereof for the preparation of a medicament for the preventive and/or curative treatment of patients suffering from or at risk of , suffering from cardiac failure.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 9, 2003 and granted July 17, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.